Hematological malignancies

There is no single model, which can allow modelling all oncohematological conditions. Blood, bone marrow, and lymph nodes are active participants of the process, and need to be assessed separately in the context of oncological disease development and progression. It is important to capture personalised donor features, such as individual expression profiles. Therefore we develop multi-donor model panels to assess the activity of drugs among the population, as well to capture the resistance